Citations

Mayo Clinic

Clear

671 citation(s) found for "Habermann, Thomas M".

Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder
Batchelor, Tracy T. , Thye, Lim Soon, Habermann, Thomas M.

American Society of Clinical Oncology Educational Book | October 29, 2018 | Volume: No volume available | Issue: 36 | Pages: e354-e366

10.1200/edbk_159030 | PMID 27249742 Get It

Primary central nervous system lymphoma, natural killer T-cell lymphoma nasal type, and post-transplant lymphoproliferative disorder are uncommon and complex lymphoproliferative disorders. These disorders present with different risk factors, have complex tumor characteristics, and require unique therapeutic interventions. These diseases require a multidisciplinary complex team approach. This article will update current management approaches and concepts.
Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?
Thanarajasingam, Gita , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Maurer, Matthew J. , Habermann, Thomas M. , Bennani, N. Nora , Cerhan, James R. , Witzig, Thomas E.

Nutrition and Cancer | September 20, 2018 | Volume: 70 | Issue: 7 | Pages: 1088-1090

10.1080/01635581.2018.1502328 | PMID 30235018 Get It

The association of physical activity before and after lymphoma diagnosis with survival outcomes
Pophali, Priyanka A. , Ip, Andrew , Flowers, Christopher R. , Link, Brian K. , Farooq, Umar , Allmer, Cristine, Cohen, Jonathon B. , Thompson, Carrie A. , Rosenthal, Allison , Witzig, T.E. , Link, Brian K , Farooq, Umar , Pophali, Priyanka , Larson, Melissa C. , Maurer, Matthew J. , Feldman, Andrew L. , Slager, Susan L. , Witzig, Thomas E. , Habermann, Thomas M. , Cerhan, James R.

American Journal of Hematology | September 19, 2018 | Volume: 93 | Issue: 12 | Pages: 1543-1550

10.1002/ajh.25288 | PMID 30230581 Get It

AbstractThe impact of physical activity (PA) on lymphoma survival is not known. The association of PA and change in PA with overall (OS), lymphoma‐specific (LSS) and event‐free (EFS) survival was evaluated in a prospective cohort of newly diagnosed lymphoma patients (2002‐2012). We calculated Leisure Score Indexes (mLSI) from the self‐reported usual adult PA (baseline) and at 3‐years post‐diagnosis (FU3), grouping patients by active vs insufficiently active by the American Cancer Society PA guidelines. Associations of PA with survival were assessed using hazard ratios (HRs) and 95% confidence intervals (CI) from Cox models stratified by lymphoma subtype, adjusted for age, sex, baseline BMI, and comorbidity score with change scores further adjusted for baseline PA. Three thousand sixty participants were evaluable at baseline and 1371 at FU3. Active patients had superior survival from baseline [HR (CI): OS 0.82 (0.72‐0.94); LSS 0.74 (0.61‐0.90); EFS 0.92 (0.82‐1.02)] and FU3 [HR (CI): OS 0.64 (0.46‐0.88); LSS 0.32 (0.18‐0.59); EFS 0.82 (0.61‐1.10)] compared to insufficiently active. An increase in mLSI from baseline to FU3 (vs stable mLSI) was associated with superior OS (HR = 0.70, CI 0.49‐1.00) and LSS (HR = 0.49, CI 0.26‐0.94).The continuous change in mLSI at FU3 was significantly associated with OS, LSS and EFS; maintained across subgroups and appeared linear. Higher PA among lymphoma patients at diagnosis and 3 years is significantly associated with OS, LSS, and EFS. Increasing PA after diagnosis is significantly associated with improved OS and LSS supporting an important role for PA in lymphoma survivorship and the need for intervention trials.
Cryptococcus neoformansinfections in patients with lymphoproliferative neoplasms
Dioverti, M. Veronica , Osmon, Douglas R. , Tande, Aaron J. , Dioverti, Maria V, Tande, Aaron , Dioverti, Maria Veronica , Parikh, Sameer A. , Habermann, Thomas M.

Leukemia & Lymphoma | September 7, 2018 | Volume: 60 | Issue: 4 | Pages: 920-926

10.1080/10428194.2018.1508666 | PMID 30188226 Get It

Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).
Abeykoon, Jithma P. , Kumar, Shaji , King, Rebecca L. , Kyle, Robert A. , Hayman, Suzanne R. , Lacy, Martha Q. , Thompson, Carrie A. , Lust, John A., Ansell, Stephen M. , Kapoor, Prashant , Paludo, Jonas , Gertz, Morie A. , Buadi, Francis K. , Habermann, Thomas M. , Dingli, David , Witzig, Thomas E. , Dispenzieri, Angela , Go, Ronald S. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7552-7552

10.1200/jco.2016.34.15_suppl.7552 Get It

Beyond maximum grade: A novel method to assess toxicity over time in clinical trials of targeted therapy in lymphoma.
Thanarajasingam, Gita , Atherton, Pamela J. , Pederson, Levi , Novotny, Paul J. , Sloan, Jeff A. , Grothey, Axel, Kumar, Shaji , Habermann, Thomas M. , Witzig, Thomas E.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7546-7546

10.1200/jco.2016.34.15_suppl.7546 Get It

Participation in clinical trials to improve outcomes of patients with relapsed lymphoma.
Nowakowski, Grzegorz S. , Ansell, Stephen M. , Macon, William R. , Ristow, Kay M., Inwards, David J. , Johnston, Patrick B. , Klebig, Robin, Micallef, Ivana N. , Markovic, Svetomir, Porrata, Luis F. , Thompson, Carrie A. , Witzig, Thomas E. , Colgan, Joseph P. , Lin, Yi , Markovic, Svetomir N. , Habermann, Thomas M.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7523-7523

10.1200/jco.2016.34.15_suppl.7523 Get It

Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma.
Tracy, Sean , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Allmer, Cristine, Macon, William R. , Maurer, Matthew J. , Witzig, Thomas E. , Drake, Matthew T. , Weiner, George J. , Slager, Susan L. , Habermann, Thomas M. , Link, Brian K. , Cerhan, James R.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e19067-e19067

10.1200/jco.2016.34.15_suppl.e19067 Get It

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).
Evens, Andrew M. , Gascoyne, Randy D. , Quon, Andrew , Ansell, Stephen M. , Petrich, Adam M., Chang, Julie , O’Brien, Timothy E., Cheema, P. , Cescon, Terrence P., Sturtz, Keren , Evens, Andrew M , Hong, Fangxin , Habermann, Thomas M. , Advani, Ranjana H. , Witzig, Thomas E. , Wagner, Lynne I. , Kahl, Brad S.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7507-7507

10.1200/jco.2016.34.15_suppl.7507 Get It